Considering the antitumor role of RNase1 in the breast TME, we then determined whether the therapeutic efficacy of cancer immunotherapies, e.g., T cell-engaging bispecific antibody (T-bsAb) 57, can be improved with the aid of RNase1. This evidence concerns the gene RNASE1 and cancer.